樂心醫療(300562.SZ)擬定增募資不超5.97億元 用於健康智能手錶生產線建設項目等
格隆匯5月19日丨樂心醫療(300562.SZ)披露2020年創業板非公開發行A股股票預案,擬非公開發行的股票數量按照募集資金總額除以發行價格確定,同時不超過此次發行前公司總股本的18%。截至預案公告日,上市公司總股本為190,296,520股,按此計算,此次非公開發行股票數量不超過34,253,373股。
募集資金總額不超過約5.97億元(含),扣除發行費用後的募集資金淨額將用於“健康智能手錶生產線建設項目”、“基於傳感器應用的智能貨架生產線建設項目”、“TWS耳機生產線建設項目”和“研發中心建設項目”四個項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.